Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 31 of the 35 references it cites were found in a registry or an index, and 3 are not checked yet; 16 of the 34 sources its claims cite were checked for support.
Abstract
BACKGROUND: Bapineuzumab, a humanized anti-amyloid-beta monoclonal antibody, is in clinical development for the treatment of Alzheimer's disease. METHODS: We conducted two double-blind, randomized, placebo-controlled, phase 3 trials involving patients with mild-to-moderate Alzheimer's disease--one involving 1121 carriers of the apolipoprotein E (APOE) ε4 allele and the other involving 1331 noncarriers. Bapineuzumab or placebo, with doses varying by study, was administered by intravenous infusion every 13 weeks for 78 weeks. The primary outcome measures were scores on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog11, with scores ranging from 0 to 70 and higher scores indicating greater impairment) and the Disability Assessment for Dementia (DAD, with scores ranging from 0 to 100 and higher scores indicating less impairment). A total of 1090 carriers and 1114 noncarriers were included in the efficacy analysis. Secondary outcome measures included findings on positron-emission tomographic amyloid imaging with the use of Pittsburgh compound B (PIB-PET) and cerebrospinal fluid phosphorylated tau (phospho-tau) concentrations. RESULTS: There were no significant between-group differences in the primary outcomes. At week 78, the between-group differences in the change from baseline in the ADAS-cog11 and DAD scores (bapineuzumab group minus placebo group) were -0.2 (P=0.80) and -1.2 (P=0.34), respectively, in the carrier study; the corresponding differences in the noncarrier study were -0.3 (P=0.64) and 2.8 (P=0.07) with the 0.5-mg-per-kilogram dose of bapineuzumab and 0.4 (P=0.62) and 0.9 (P=0.55) with the 1.0-mg-per-kilogram dose. The major safety finding was amyloid-related imaging abnormalities with edema among patients receiving bapineuzumab, which increased with bapineuzumab dose and APOE ε4 allele number and which led to discontinuation of the 2.0-mg-per-kilogram dose. Between-group differences were observed with respect to PIB-PET and cerebrospinal fluid phospho-tau concentrations in APOE ε4 allele carriers but not in noncarriers. CONCLUSIONS: Bapineuzumab did not improve clinical outcomes in patients with Alzheimer's disease, despite treatment differences in biomarkers observed in APOE ε4 carriers. (Funded by Janssen Alzheimer Immunotherapy and Pfizer; Bapineuzumab 301 and 302 ClinicalTrials.gov numbers, NCT00575055 and NCT00574132, and EudraCT number, 2009-012748-17.).
Verified 2026-10-06 · 3 references not checked yet
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 0 Not valid · 8 Not checked · 44 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The greater incidence of these abnormalities with increasing bapineuzumab dose and number of APOEε4 alleles is consistent with phase 2 findings.11,13”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > DISCUSSION
What the sources say
- Supportedcites [11] Sperling R Salloway S Brooks DJ Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis Lancet Neurol 2012 11 241 9 22305802 PMC4063417 source
The Methods identify the scans as coming from phase 2 bapineuzumab studies 201 and 202 and their extension study 251. The Results report that ARIA-E incidence increased with both bapineuzumab dose and the number of APOE ε4 alleles. Page numbers are not available in our copy. (LLM, conf=0.94)
- Supportedcites [13] Salloway S Sperling R Gilman S A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease Neurology 2009 73 2061 70 19923550 PMC2790221 source
The Abstract reports that MRI-detected vasogenic edema was more frequent in higher bapineuzumab dose groups. The Safety section reports increasing edema rates with APOE ε4 gene dose: 4.3% with zero copies, 7.1% with one, and 33.3% with two. The supplied passages do not give page numbers. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Partly supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 sourceExperimental — accuracy not yet measured
The Results and Discussion (page unavailable) identify 3D6 as an antibody that reduced plaque burden in PDAPP transgenic mice. They do not report that 3D6 improved memory; the paper’s mention of improved object-recognition performance concerns a different antibody directed against the midportion of Aβ. (LLM, conf=0.86)
- Partly supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 sourceExperimental — accuracy not yet measured
The Results report that 3D6 treatment protected synapses in transgenic PDAPP mice, and Figure 4 (Discussion; page not specified) reports improved synaptophysin levels. The paper does not report a memory test or show that 3D6 improved memory; synaptic protection does not establish that outcome. (LLM, conf=0.84)
- Could not verifycites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The antibody-results passage (section labeled Abstract; page unavailable) reports that 3D6 precipitated soluble Aβ and prevented a synaptic-plasticity deficit. The memory experiment in the same section used normal rats and did not test 3D6. Searches for 3D6 and for antibody treatment in transgenic mice found no passage showing that 3D6 improved their memory. (LLM, conf=0.76)
- Supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 source
The Results section, “The N-terminal anti-Aβ mAb 3D6 acutely reverses CFC deficit in Tg2576 mice” (Fig. 6), reports that 3D6 completely reversed a contextual fear-conditioning deficit in transgenic mice overexpressing human amyloid precursor protein. The Introduction identifies 3D6 as the murine antibody from which bapineuzumab was humanized. Together, these passages support the attributed improvement in a memory-related task. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Amyloid accumulation probably starts many years before the onset of symptoms,2,26,27 and initiation of anti-amyloid treatment only after dementia develops may be too late to affect the clinical course of the disease.28”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > DISCUSSION
What the sources say
- Supportedcites [2] Bateman RJ Xiong C Benzinger TL Clinical and biomarker changes in dominantly inherited Alzheimer’s disease N Engl J Med 2012 367 795 804 [Erratum, N Engl J Med 2012;367:780.] 22784036 PMC3474597 source
The Results (Combined Model) report Aβ deposition detected at least 15 years before expected symptom onset in mutation carriers. The Discussion also says amyloid deposition probably occurs years or decades before dementia symptoms in sporadic Alzheimer’s disease. (LLM, conf=0.93)
- Supportedcites [26] Jack CR Jr Knopman DS Jagust WJ Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade Lancet Neurol 2010 9 119 28 20083042 PMC2819840 source
In “Biomarker abnormalities precede clinical symptoms,” the paper says that calculated rates from serial PiB imaging indicate Aβ-plaque accumulation might begin as much as two decades before clinical symptoms in individuals destined to develop dementia. That supports the cited claim’s qualified wording, “probably starts many years before.” The separate treatment claim in the citing sentence is attached to citation 28, not this source. (LLM, conf=0.94)
- Not checked yetcites [27] Villemagne VL Burnham S Bourgeat P Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study Lancet Neurol 2013 12 357 67 23477989 source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 source
The Results and Discussion (page unavailable) identifies 3D6 among antibodies previously effective at reducing plaque burden in vivo. The paper describes those brain plaques as containing Aβ, supporting the attributed preclinical reduction in brain Aβ. (LLM, conf=0.88)
- Supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 source
The Results report significantly reduced brain Aβ levels after passive immunization with N-terminal anti-Aβ antibodies. The Methods identify 3D6 as an anti-Aβ(1–5) antibody, and the Figure 4 caption confirms that PDAPP mice received 3D6 as a passive immunization treatment. Page numbers are unavailable in our copy. (LLM, conf=0.91)
- Partly supportedcites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The passage on antibody co-administration (section labeled Abstract; page unavailable) reports that 3D6 almost completely precipitated soluble Aβ from extracts of human Alzheimer’s brains. That is an ex vivo finding, not evidence that administering 3D6 reduces Aβ levels in the brain in preclinical animals. (LLM, conf=0.78)
- Supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 source
The Abstract reports that preclinical studies of 3D6, the murine form of bapineuzumab, demonstrated resolution of Aβ plaque and vascular burdens in transgenic mice. The Introduction likewise describes enhanced clearance of insoluble Aβ in the brain and cerebral vasculature, supporting the claim that 3D6 reduces brain Aβ. (LLM, conf=0.89)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In preclinical studies, the murine form of the antibody (3D6) was shown to bind to fibrillar, oligomeric, and monomeric forms of Aβ, reduce the amount of Aβ in the brain, and improve memory in transgenic mice that overproduced Aβ.4–8”
§ Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer’s Disease > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [4] Bard F Cannon C Barbour R Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat Med 2000 6 916 9 10932230 source
- Partly supportedcites [5] Bard F Barbour R Cannon C Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer’s disease-like neuropathology Proc Natl Acad Sci U S A 2003 100 2023 8 [Erratum, Proc Natl Acad Sci U S A 2004;101:11526.] 12566568 PMC149952 sourceExperimental — accuracy not yet measured
Table 1 in Results and Discussion (page unavailable) reports that 3D6 binds amyloid plaques in PDAPP mice, supporting binding to deposited Aβ. It does not report that 3D6 binds oligomeric or monomeric Aβ; the aggregated-versus-soluble binding measurements concern other antibodies. (LLM, conf=0.82)
- Partly supportedcites [6] Buttini M Masliah E Barbour R Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer’s disease J Neurosci 2005 25 9096 101 16207868 PMC6725749 sourceExperimental — accuracy not yet measured
The antibody-generation section identifies 3D6 as an antibody against Aβ(1–5), and the methods describe its use to stain amyloid plaques. Our copy does not establish that 3D6 binds each of the fibrillar, oligomeric, and monomeric forms of Aβ; searches for those forms found no binding results. (LLM, conf=0.83)
- Partly supportedcites [7] Shankar GM Li S Mehta TH Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory Nat Med 2008 14 837 42 18568035 PMC2772133 sourceExperimental — accuracy not yet measured
The paper reports that 3D6 immunoprecipitated soluble Aβ from Alzheimer’s brain extracts; its discussion of 3D6-immunoprecipitated material includes dimers and monomers (Abstract, page unavailable). Our copy does not show that 3D6 binds fibrillar Aβ, so the claim’s full list of forms is not supported. (LLM, conf=0.84)
- Partly supportedcites [8] Zago W Buttini M Comery TA Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific J Neurosci 2012 32 2696 702 22357853 PMC6621896 sourceExperimental — accuracy not yet measured
The section “Binding of the N-terminal antibody 3D6 to soluble Aβ species” reports that 3D6 binds soluble, oligomer-enriched Aβ. The Introduction describes clearance of insoluble Aβ, but the passages do not establish direct binding to fibrillar or monomeric Aβ. Those two specified forms are therefore not fully supported by this source. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 57 claims and to verify the 18 references still open.
- It may state two separate claims as one. 6
- Probably not a substantial claim. 9
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Following the completion of the first two studies, which revealed no treatment efficacy on either cognitive or functional outcomes, further trials were halted (Salloway et al., 2014).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Salloway et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bapineuzumab was the first monoclonal antibody to target Aβ in AD using a passive immunotherapy technique.”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Salloway et al., 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Supporting this idea, studies have shown that extracellular amyloid deposition correlates poorly with the degree of cognitive decline in AD [10], in agreement with the results obtained in clinical trials showing that Aβ-targeted immunotherapies removing Aβ deposition in the brain do not result in cognitive improvement [99].”
From Senescence-related impairment of autophagy induces toxic intraneuronal amyloid-β accumulation in a mouse model of amyloid pathology (2023) · cites this paper as [99]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further trials were discontinued after the first two trials were completed and yielded no treatment effect on either cognitive or functional outcomes [41].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [41]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and a similar proportion has normal amyloid PET or CSF Aβ42 studies [53–62].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [56]
Experimental — accuracy not yet measured
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Cited by
Items 801–900 of 1,014
Hong, Z., Yu, S., Wang, Z., & Zhu, Y. Z. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160818544 · Cited by 36
Li, C., Guo, X., Lei, M., Wu, J., Jin, J.-Z., Shi, X., Zhu, Z., Rukachaisirikul, V., Hu, L., Wen, T., et al. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.94 · Cited by 36
Liu, M., Jevtic, S. D., Markham-Coultes, K., Ellens, N. P. K., O’Reilly, M. A., Hynynen, K., Aubert, I., & McLaurin, J. (2017) · Brain Research · doi:10.1016/j.brainres.2017.10.015 · Cited by 37
Clinical trials of prion disease therapeutics
Forloni, G., Roiter, I., & Tagliavini, F. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.04.019 · Cited by 37
Li, C., Zhou, L., & Yin, X. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1342181 · Cited by 41
“Compared to non-targeted formulations, the signal intensity variation is more pronounced in mice with C6 glioma when Tf-targeted NPs are administered (Korkusuz et al., 2013).”
BackgroundLi, Y., Liu, C., Sun, J., Zhang, J., Li, X., & Zhang, Z. (2024) · Journal of Medical Internet Research · doi:10.2196/59684 · Cited by 41
Alzheimer’s Disease: From Molecular Mechanisms to Promising Therapeutic Strategies
Ivanova, A. V., Kutuzova, A. D., Kuzmichev, I. A., & Abakumov, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199444 · Cited by 35
Brody, M., Liu, E., Di, J., Lu, M., Margolin, R. A., Werth, J. L., Booth, K., Shadman, A., Brashear, H. R., & Novak, G. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160369 · Cited by 32
“This may be due to the duration of SC bapineuzumab treat-ment (reduced from 24 months to 12 months), which is less than the duration (78 weeks) that was found to be effective in reducing PET SUVR in previous studies of IV bapineuzumab [3].”
InfluentialSelf-citationInhibiting the Ca2+ Influx Induced by Human CSF
Drews, A., De, S., Flagmeier, P., Wirthensohn, D. C., Chen, W.-H., Whiten, D. R., Rodrigues, M., Vincke, C., Muyldermans, S., Paterson, R. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.057 · Cited by 32
“We have in the past lacked the techniques needed to measure and quantify effectively such species present in vivo, for example, in human cerebrospinal fluid (CSF), where the concentrations are approximately 1 pM (Sav- age et al., 2014; Yang et al., 2015).”
Self-citationSingle-Molecular Heteroamyloidosis of Human Islet Amyloid Polypeptide
Käkinen, A., Xing, Y., Arachchi, N. D. H., Javed, I., Feng, L., Faridi, A., Douek, A. M., Sun, Y., Kaslin, J., Davis, T. P., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b02771 · Cited by 32
Suzuki, K., Hirakawa, A., Ihara, R., Iwata, A., Ishii, K., Ikeuchi, T., Sun, C., Donohue, M., Iwatsubo, T., & Alzheimer's Disease Neuroimaging Initiative, J. A. D. N. I. (2020) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12007 · Cited by 43
Bullich, S., Mueller, A., Santi, S. D., Koglin, N., Krause, S., Kaplow, J. M., Kanekiyo, M., Roé-Vellvé, N., Perrotin, A., Jovalekic, A., et al. (2022) · Alzheimer s Research & Therapy · doi:10.1186/s13195-022-01048-x · Cited by 35
“With the negative outcomes of several therapeutic clinical trials in reducing the cognitive decline in mild-to-moderate AD [17, 18], investigators were encouraged to explore treatment effects in the earliest possible phase of biomarkers abnormalities event at the asymptomatic stage.”
BackgroundYan, H., Feng, L., & Li, M. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s380612 · Cited by 35
“58,59 62 According to Elena et al 57 neurogenesis is still observed in the brains of healthy individuals up to the age of 90.”
BackgroundTargeting β-Amyloid Plaques and Oligomers: Development of Near-Ir Fluorescence Imaging Probes
Liu, H., Yang, J., Wang, L., Xu, Y., Zhang, S., Lv, J., Ran, C., & Li, Y. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0185 · Cited by 33
Presotto, L., Iaccarino, L., Sala, A., Vanoli, E. G., Muscio, C., Nigri, A., Bruzzone, M. G., Tagliavini, F., Gianolli, L., Perani, D., et al. (2018) · NeuroImage Clinical · doi:10.1016/j.nicl.2018.07.013 · Cited by 36
“T outcome measure as well (Salloway et al., 2014; Sevigny et al., 2016).”
Nanotechnology in the diagnostic and therapy for Alzheimer's disease
Panghal, A., & Flora, S. J. S. (2024) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2024.130559 · Cited by 31
The Impact of Anti-Amyloid Immunotherapies on Stroke Care
Bilodeau, P., Dickson, J. R., & Kozberg, M. G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051245 · Cited by 33
Therapeutic role of neural stem cells in neurological diseases
Yang, L., Liu, S., Liu, Y., Zhu, F.-Q., Xiong, M.-J., Hu, D.-X., & Zhang, W.-J. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1329712 · Cited by 39
“Thirdly, the loss of a large number of neurons and synapses is the most closely related factor of early cognitive decline in AD (Delbeuck et al., 2003; Salloway et al., 2014; Duncan and Valenzuela, 2017; Fang et al., 2019).”
BackgroundIncreases in amyloid-β42 slow cognitive and clinical decline in Alzheimer’s disease trials
Abanto, J. T., Dwivedi, A. K., Imbimbo, B. P., & Espay, A. J. (2024) · Brain · doi:10.1093/brain/awae216 · Cited by 39
Jin, M., & Noble, J. M. (2024) · eNeuro · doi:10.1523/eneuro.0088-24.2024 · Cited by 39
“…in a new RCT. Collectively, results of the aducanumab trials re fl ected outcomes of several other anti-A β MAB trials demonstrating variable levels of convincing amyloid target engagement but disappointing clinical impacts (Salloway et al., 2014, 2021; Honig et al., 2018; Bateman et al., 2023).”
ResultInterpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β
Toyn, J. H., & Ahlijanian, M. K. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt244 · Cited by 39
Insights into Mechanisms of Chronic Neurodegeneration
Diack, A. B., Alibhai, J. D., Barron, R. M., Bradford, B. M., Piccardo, P., & Manson, J. C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010082 · Cited by 34
“Diagnosis of these diseases often occurs at the latter stages when clinical signs become evident; however, therapeutic interventions have little effect at this stage [16–18].”
BackgroundEmerging Approaches to Investigate the Influence of Transition Metals in the Proteinopathies
Lermyte, F., Everett, J. L., Brooks, J., Bellingeri, F., Billimoria, K., Sadler, P. J., O’Connor, P. B., Telling, N. D., & Collingwood, J. F. (2019) · Cells · doi:10.3390/cells8101231 · Cited by 31
Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
Imbimbo, B. P., Lozupone, M., Watling, M., & Panza, F. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1795127 · Cited by 31
Ricci, M., Cimini, A., Chiaravalloti, A., Filippi, L., & Schillaci, O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207481 · Cited by 39
“Although these trials have so far produced disappointing results in terms of cognitive benefit, some have demonstrated a modest reduction in cerebral amyloidosis and encouraging clinical results [31,32].”
ResultGroot, C., Grothe, M. J., Mukherjee, S., Jelistratova, I., Jansen, I. E., van Loenhoud, A. C., Risacher, S. L., Saykin, A. J., Donald, C. L. M., Mez, J., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102660 · Cited by 33
“…MMSE was selected to measure global cognition and progression as it is a widely implemented test to examine clinical progression in clinical practice (Doody et al., 2001) and clinical trials (Doody et al., 2014; Salloway et al., 2014), and is administered at every follow-up visit in the ADC cohort.”
Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials
Soejitno, A., Tjan, A., & Purwata, T. E. (2015) · CNS Drugs · doi:10.1007/s40263-015-0257-8 · Cited by 35
“Given the less equipped information gathered from the phase I study, it was no surprise when the phase II and III trials failed to demonstrate any cognitive improvements in the treatment group, although the levels of p-tau were found to decrease [108, 109].”
MethodRyan, N. S., Lashley, T., Révész, T., Dantu, K., Fox, N. C., & Morris, H. R. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142325 · Cited by 33
“for AD [1–5].”
BackgroundSelf-citationSpecific Amyloid β Clearance by a Catalytic Antibody Construct
Planque, S. A., Nishiyama, Y., Sonoda, S., Lin, Y., Taguchi, H., Hara, M., Kolodziej, S. J., Mitsuda, Y., González‐Calle, V., Sait, H. B. R., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.641738 · Cited by 32
“In addition to deposits of A (1– 42) (A 42) that damage the brain parenchyma, accumulation of A (1– 40) (A 40) in blood vessel walls causes microvasculature-related neuroinflammation and compromised blood-brain barrier (BBB) integrity (2), resulting in cerebral amyloid angiopathy (CAA) in nearly all AD patients (3).”
BackgroundInfluentialAPP Overexpression Causes Aβ-Independent Neuronal Death through Intrinsic Apoptosis Pathway
Cheng, N., Jiao, S., Gumaste, A., Bai, L., & Belluscio, L. (2016) · eNeuro · doi:10.1523/eneuro.0150-16.2016 · Cited by 31
Innate immunity in Alzheimer’s disease: the relevance of animal models?
Franco Bocanegra, D. K., Nicoll, J. A. R., & Boche, D. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-017-1729-4 · Cited by 30
Cheng, B., Li, Y., Ma, L., Wang, Z., Petersen, R. B., Zheng, L., Chen, Y., & Huang, K. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.02.013 · Cited by 33
Marazuela, P., Paez-Montserrat, B., Bonaterra-Pastra, A., Solé, M., & Hernández-Guillamon, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094972 · Cited by 31
Lecanemab: More Questions Than Answers!
Kaur, U., Reddy, J., Tiwari, A., Chakrabarti, S., & Chakrabarti, S. S. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01331-1 · Cited by 31
Tonegawa‐Kuji, R., Hou, Y., Hu, B., Lorincz‐Comi, N. J., Pieper, A. A., Tousi, B., Leverenz, J. B., & Cheng, F. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004568 · Cited by 36
Antibody-based therapies for Huntington’s disease: current status and future directions
Denis, H. L., David, L. S., & Cicchetti, F. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104569 · Cited by 55
Influence of Comorbidity of Cerebrovascular Disease and Amyloid-β on Alzheimer’s Disease
Yassi, N., Hilal, S., Xia, Y., Lim, Y. Y., Watson, R., Kuijf, H. J., Fowler, C. J., Yates, P. A., Maruff, P. T., Martins, R. N., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-191028 · Cited by 32
Longitudinal plasma amyloid beta in Alzheimer's disease clinical trials
Donohue, M., Moghadam, S. H., Roe, A. D., Sun, C., Edland, S. D., Thomas, R. G., Petersen, R. C., Sano, M., Galasko, D. R., Aisen, P. S. S., et al. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.07.156 · Cited by 32
“Although the authors concluded that these associations are not strong enough to support use of plasma A b as a diagnostic screening test, these and those observed in immunotherapy trials (e.g. [ 39], for review [40]) suggests that plasma A b 42 may be useful as a pharmacodynamic marker.”
ResultLenox‐Smith, A., Reed, C. C., Lebrec, J., Belger, M. A., & Jones, R. W. (2016) · BMC Geriatrics · doi:10.1186/s12877-016-0371-6 · Cited by 34
Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies
Shin, J. H., Kim, H., & Jeon, B. (2019) · Journal of Movement Disorders · doi:10.14802/jmd.19057 · Cited by 32
Dantas, J. M., Mutarelli², A. M., Navalha, D. D. P., Dagostin, C. S., Romeiro, P. H. C. L., Felix, N. S., Nogueira, A., Batista, S., Teixeira, L., & Caramelli, P. (2023) · Neurological Sciences · doi:10.1007/s10072-023-07194-w · Cited by 32
Gong, B., Zhang, W., Cong, W., Gu, Y., Ji, W., Yin, T., Zhou, H., Hu, H., Zhuang, J., Luo, Y., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400149 · Cited by 44
Modeling Alzheimer’s disease using human cell derived brain organoids and 3D models
Fernandes, S., Revanna, J. S., Pratt, J. M., Hayes, N., Marchetto, M. C., & Gage, F. H. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1434945 · Cited by 46
Challenges in a Biological Definition of Alzheimer Disease
Hazan, J., Liu, K. Y., Costello, H., Isaacs, J. D., Thambisetty, M., & Howard, R. J. (2024) · Neurology · doi:10.1212/wnl.0000000000209884 · Cited by 34
Bispecific brain-penetrant antibodies for treatment of Alzheimer’s disease
Sehlin, D., Hultqvist, G., Michno, W., Aguilar, X., Dahlén, A. D., Cerilli, E., Bucher, N. M., van den Broek, S. L., & Syvänen, S. (2025) · The journal of prevention of Alzheimer's disease · doi:10.1016/j.tjpad.2025.100214 · Cited by 30
Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
Ritter, A. R., & Cummings, J. L. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00186 · Cited by 34
“For example, in the Phase III trial of bapineuzumab >35% of APOE ε4 non-carriers had negative amyloid scans (70).”
BackgroundImaging as a biomarker in drug discovery for Alzheimer’s disease: is MRI a suitable technology?
Pich, E. M., Jeromin, A., Frisoni, G. B., Hill, D., Lockhart, A., Schmidt, M. E., Turner, M. R., Mondello, S., & Potter, W. Z. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt276 · Cited by 30
Intracellular FRET-based Screen for Redesigning the Specificity of Secreted Proteases
Guerrero, J. L., O’Malley, M., & Daugherty, P. S. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01051 · Cited by 29
A Theoretical Analysis of the Synergy of Amyloid and Tau in Alzheimer’s Disease
Han, P., & Shi, J. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151206 · Cited by 33
“Recent clinical trials targeting A have produced less than expected cognitive benefits, although they improved A -associated biomarkers [3–6].”
Tian, J., Shi, J., Wei, M., Ni, J., Fang, Z., Gao, J., Wang, H., Yao, H., Zhang, J., Li, J., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.03.001 · Cited by 31
Chen, G., Yang, K. Y., Du, W., Hu, X., & Han, Y. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190501 · Cited by 30
“Current anti-amyloid approaches to prevent, delay, and treat AD are not effective for patients with mild to moderate AD dementia [3–7].”
Overexpression of wild-type human amyloid precursor protein alters GABAergic transmission
Kreis, A., Desloovere, J., Suelves, N., Pierrot, N., Yerna, X., Issa, F., Schakman, O., Gualdani, R., de Clippele, M., Tajeddine, N., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-97144-3 · Cited by 33
Autophagy is involved in oral rAAV/Aβ vaccine-induced Aβ clearance in APP/PS1 transgenic mice
Wang, H.-C., Zhang, T., Kuerban, B., Jin, Y.-L., Le, W., Hara, H., Fan, D.-S., Wang, Y., Tabira, T., & Chui, D.-H. (2015) · Neuroscience Bulletin · doi:10.1007/s12264-015-1546-4 · Cited by 30
Lacey, L. A., Bobula, J. D., Rüdell, K., Alvir, J. M., & Leibman, C. (2015) · Value in Health · doi:10.1016/j.jval.2015.03.1787 · Cited by 29
Ong, S. S. Y., Proia, A. D., Whitson, H. E., Farsiu, S., Doraiswamy, P. M., & Lad, E. M. (2018) · Journal of Neurology · doi:10.1007/s00415-018-9028-z · Cited by 33
Beyond amyloid and tau: rethinking Alzheimer’s disease through less explored avenues
Gyimesi, M., Okolicsanyi, R. K., & Haupt, L. M. (2024) · Open Biology · doi:10.1098/rsob.240035 · Cited by 33
Alzheimer disease: Amyloid peptide controversies and challenges of anti-Aβ immunotherapy
Almohmadi, N. H., Al-Kuraishy, H. M., Albuhadily, A. K., Al-Gareeb, A. I., Abdelaziz, A. M., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103639 · Cited by 30
“64,65 A double-blind, randomized, placebo-controlled, phase 3 trial involving patients with mild-to-moderate AD, with one group of 1121 carriers of the apolipoprotein E ( APOE ) ε 4 allele and the other with 1331 noncarriers showed that bapineuzumab did not improve clinical outcomes in AD patients…”
Izumi, H., Shinoda, Y., Saito, T., Saido, T. C., Sato, K., Yabuki, Y., Matsumoto, Y., Kanemitsu, Y., Tomioka, Y., Abolhassani, N., et al. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.02.031 · Cited by 29
Zhao, L., Initiative, A. D. N., Luo, Y., Lew, D., Liu, W., Au, L. W. C., Mok, V., & Shi, L. (2019) · Aging · doi:10.18632/aging.102184 · Cited by 33
The Protective A673T Mutation of Amyloid Precursor Protein (APP) in Alzheimer’s Disease
Xia, Q., Yang, X., Shi, J., Liu, Z., Peng, Y., Wang, W., Li, B., Zhao, Y., Xiao, J., Huang, L. F., et al. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02385-y · Cited by 34
“However, in recent years, some secretory enzyme inhibitors and immunotherapy experiments have failed continuously, such as the failure of Bapineuzumab and Solanezumab for moderate AD, and the related anti-Aβ research has been signi cantly reduced [68-73].”
BackgroundSelf-citationThe Current Landscape of Prevention Trials in Dementia
Lee, J., Howard, R. S., & Schneider, L. S. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01236-5 · Cited by 33
Loftus, J. R., Puri, S., & Meyers, S. P. (2023) · Insights into Imaging · doi:10.1186/s13244-022-01358-6 · Cited by 33
Salemme, S., Ancidoni, A., Locuratolo, N., Piscopo, P., Lacorte, E., Canevelli, M., & Vanacore, N. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2284305 · Cited by 28
Piechotta, A., Parthier, C., Kleinschmidt, M., Gnoth, K., Pillot, T., Lues, I., Demuth, H., Schilling, S., Rahfeld, J., & Stubbs, M. T. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.777839 · Cited by 29
A Toxic Conformer of Aβ42 with a Turn at 22–23 is a Novel Therapeutic Target for Alzheimer’s Disease
Izuo, N., Kasahara, C., Murakami, K., Kume, T., Maeda, M., Irie, K., Yokote, K., & Shimizu, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-11671-6 · Cited by 31
Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond
Garmendia, J. V., Sanctis, C. V. D., Das, V., Annadurai, N., Hajdúch, M., & Sanctis, J. B. D. (2023) · Current Neuropharmacology · doi:10.2174/1570159x22666231017141636 · Cited by 30
A framework for translating tauopathy therapeutics: Drug discovery to clinical trials
Feldman, H., Cummings, J. L., Boxer, A. L., Staffaroni, A. M., Knopman, D. S., Rizzo, S. J. S., Territo, P. R., Arnold, S. E., Ballard, C. G., Beher, D., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14250 · Cited by 28
Panza, F., Dibello, V., Sardone, R., Zupo, R., Castellana, F., Leccisotti, I., Moretti, M. C., Altamura, M., Bellomo, A., Daniele, A., et al. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2463963 · Cited by 30
“Overall, in Phase II/III RCTs, these compounds had marks of efficiency in Aβ clearance and cognitive benefits [40–42].”
The Positive Effects of Viewing Gardens for Persons with Dementia
Goto, S., Shen, X., Sun, M., Hamano, Y., & Herrup, K. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170510 · Cited by 36
Linking Late Life Depression and Alzheimer’s Disease: Mechanisms and Resilience
Weisenbach, S. L., Kim, J. U., Hammers, D. B., Konopacki, K. L., & Koppelmans, V. (2019) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-019-00180-7 · Cited by 33
Smedinga, M., Darweesh, S. K. L., Bloem, B. R., Post, B., & Richard, E. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10162-5 · Cited by 29
Reiss, A. B., Montufar, N., DeLeon, J. R., Pinkhasov, A., Gomolin, I. H., Glass, A. D., Arain, H. A., & Stecker, M. M. (2021) · The Neurologist · doi:10.1097/nrl.0000000000000320 · Cited by 28
Recent advance on pleiotropic cholinesterase inhibitors bearing amyloid modulation efficacy
Zhang, H., Peng, Y., Zhuo, L., Wang, Y., Guo, Z., Wang, S., Long, L., Li, X., & Wang, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114695 · Cited by 27
Jin, M., Wang, S., Gao, X., Zou, Z., Hirotsune, S., & Sun, L. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.382231 · Cited by 28
“After some failures in clinical trials, such as those of bapineuzumab, solanezumab, and crenezumab (Salloway et al., 2014; Cummings et al., 2018; Honig et al., 2018), some monoclonal antibodies are now making it through to the late phase of clinical development.”
MethodEpelbaum, S., Youssef, I., Lacor, P. N., Chaurand, P., Duplus, E., Brugg, B., Duyckaerts, C. J., & Delatour, B. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.03.005 · Cited by 44
Martins, A. F., Oliveira, A. C., Morfin, J., Laurents, D. V., Tóth, É., & Geraldes, C. F. G. C. (2015) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-015-1316-9 · Cited by 28
Chen, J., Zhang, T., Jiao, S., Zhou, X., Zhong, J., Wang, Y., Liu, J., Deng, J., Wang, S., & Xu, Z. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161191 · Cited by 29
“Much effort has been made to treat the disease by removing the A (cid:2) deposition in the brains of AD patients, including several clinical trials of immunotherapy in recent years [22–24].”
Neumann, U., Machauer, R., & Shimshek, D. R. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14582 · Cited by 28
“Furthermore, major severe side effects of Aβ‐directed immunotherapies are vasogenic oedema and cerebral microhaemorrhage (Mo, Li, Yang, Liu, & Feng, 2017; Salloway et al., 2014; Sperling et al., 2012).”
BackgroundJeong, S. Y., Suh, C. H., Kim, S. J., Lemere, C. A., Lim, J.-S., & Lee, J.-H. (2024) · Korean Journal of Radiology · doi:10.3348/kjr.2024.0105 · Cited by 26
Abushakra, S. R., Power, A., Watson, D., Porsteinsson, A. P., Sabbagh, M., MacSweeney, E., Cohen, S., Boada, M., Doraiswamy, P. M., Liang, E., et al. (2025) · Drugs · doi:10.1007/s40265-025-02250-5 · Cited by 33
Self-citationTosun, D., Chen, Y.-F., Yu, P., Sundell, K. L., Suhy, J., Siemers, E., Schwarz, A. J., Weiner, M. W., & Initiative, A. D. N. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.009 · Cited by 27
“Analysis of A b biomarker subgroups in phase 3 clinical trials from two independent drug development programs revealed that approximately 27% of subjects meeting clinical inclusion criteria for mild-AD were A b -negative [4,5].”
Wang, M. J., Yi, S., Han, J.-Y., Park, Y. H., Jang, J., Chun, I. K., Giau, V. V., Bagyinszky, E., Lim, K., Kang, S. M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160143 · Cited by 28
“Reports from drug trial studies show that 10% to 30% of clinically diagnosed AD cases have no evidence of amyloid pathology on amyloid positron emission tomography (PET) scans [2].”
Kuo, Y., & Rajesh, R. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1621750 · Cited by 28
“neuzumab against Aβ accumulation [23], increased unbound of solanezumab to Aβ42 [24], adverse gastrointestinal and urinary effects of leucomethylthioninium bis(hydromethanesulfonate) at a high dose [25], poor toleration with trends toward cognitive worsening of γ-secretase inhibitor (GSI), avagacestat at”
BackgroundSoloperto, A., Quaglio, D., Baiocco, P., Romeo, I., Mori, M., Ardini, M., Presutti, C., Sannino, I., Ghirga, S., Iazzetti, A., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-09016-z · Cited by 29
Aducanumab: A new hope in Alzheimer's disease
Ali, R., Gupta, G. D., & Chawla, P. A. (2022) · Health Sciences Review · doi:10.1016/j.hsr.2022.100039 · Cited by 37
Hu, C., Adedokun, O. J., Ito, K., Raje, S. V., & Lu, M. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.393 · Cited by 26
“The study designs and patient inclusion criteria for Study ELN115727-301 and Study ELN115727-302 have been previously described.(12) Briefly, in Study ELN115727-301, 787 patients (69.”
BackgroundVoyle, N., Kim, M., Proitsi, P., Ashton, N. J., Baird, A. L., Bazenet, C. E., Hye, A., Westwood, S., Chung, R., Ward, M. A., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2015.205 · Cited by 30
Davis, P. R., Giannini, G., Rudolph, K., Calloway, N. T., Royer, C. M., Beckett, T. L., Murphy, M. P., Bresch, F., Pagani, D., Platt, T. L., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.09.007 · Cited by 30
Xia, C., & Dickerson, B. C. (2017) · PET Clinics · doi:10.1016/j.cpet.2017.02.005 · Cited by 31
Cleavage of potassium channel Kv2.1 by BACE2 reduces neuronal apoptosis
Liu, F., Zhang, Y., Liang, Z., Sun, Q., Liu, H., Zhao, J., Xu, J., Zheng, J., Yun, Y., Yu, X., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0060-2 · Cited by 27
A guide to using functional magnetic resonance imaging to study Alzheimer's disease in animal models
Asaad, M., & Lee, J. H. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.031724 · Cited by 27
“This disconnect could explain why some treatments that improve cognition in animals fail to do so in human patients (Doody et al., 2014; Holmes et al., 2008; Salloway et al., 2014; Vellas et al., 2013).”
Neuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer’s Disease: Are We There Yet?
Raikwar, S. P., Thangavel, R., Dubova, I., Ahmed, M. E., Selvakumar, G. P., Kempuraj, D., Zaheer, S. A., Iyer, S. S., & Zaheer, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180422 · Cited by 32
A short perspective on the long road to effective treatments for Alzheimer's disease
Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 30
Esquerda-Canals, G., Roda, A. R., Martí, J., Montoliu‐Gaya, L., Rivera-Hernández, G., & Villegas, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190484 · Cited by 29
“Differences in neuroinflam-matory responses pose a problem in the translation of preclinical animal trials to human trials, as demonstrated previously in clinical trials [50, 51].”
Cao, K., Dong, Y., Xiang, J., Xu, Y., Li, Y., Song, H., Yu, W., Qi, X., & Guan, Z.-Z. (2019) · Aging · doi:10.18632/aging.102713 · Cited by 27
Alzheimer's Disease: Many Failed Trials, So Where Do We Go from Here?
Reiss, A. B., Glass, A. D., Wısnıewskı, T., Wolozin, B. L., Gomolin, I. H., Pinkhasov, A., Leon, J. D., & Stecker, M. M. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2020-001297 · Cited by 27
Brain metastasis models: What should we aim to achieve better treatments?
Masmudi‐Martín, M., Zhu, L., Sánchez‐Navarro, M., Priego, N., Casanova-Acebes, M., Ruiz‐Rodado, V., Giralt, E., & Valiente, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.002 · Cited by 27
Immunotherapy for Parkinson’s Disease and Alzheimer’s Disease: A Promising Disease-Modifying Therapy
Mahboob, A., Ali, H., Naimi, A. J. A., Yousef, M., Rob, M., Al-Muhannadi, N. A., Senevirathne, D. K. L., & Châari, A. (2024) · Cells · doi:10.3390/cells13181527 · Cited by 31
Lenox‐Smith, A., Reed, C. C., Lebrec, J., Belger, M. A., & Jones, R. W. (2018) · BMC Geriatrics · doi:10.1186/s12877-018-0748-9 · Cited by 27
Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases
McAlary, L., Plotkin, S. S., & Cashman, N. R. (2019) · CNS Drugs · doi:10.1007/s40263-019-00657-9 · Cited by 28
Metadata
- Authors
- Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. C., Liu, E., Grundman, M., Yuen, E., Black, R., & Brashear, H. R.
- Affiliations
- Brigham and Women's Hospital (US)
- UCL Queen Square Institute of Neurology (GB)
- Sahlgrenska University Hospital (SE)
- University of Pittsburgh (US)
- Veterans Health Administration (US)
- Columbia University (US)
- University of Rochester Medicine (US)
- NYU Langone Health (US)
- Janssen Alzheimer Immunotherapy Research & Development (United States) (US)
- University of California San Diego (US)
- Pfizer (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-01-23
- Volume
- 370
- Issue
- 4
- Pages
- 322-333
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4159618
- OpenAlex
- W2063808031
- Semantic Scholar
- e062a2c7d07a68f95ef3d0dad78aaa50b786274d
- Cited by
- 1,960
- References
- 35
- Citations by year
- 2026: 71 · 2025: 102 · 2024: 151 · 2023: 131 · 2022: 127 · 2021: 144 · 2020: 180 · 2019: 173 · 2018: 162 · 2017: 184 · 2016: 200 · 2015: 208 · 2014: 123
- FWCI
- 158.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- U.S. Department of Veterans Affairs (IK2 BX001820)
- National Institute for Health and Care Research (NF-SI-0513-10134, NF-SI-0508-10123)
- Medical Research Council (MR/L501517/1, MR/L010305/1, MR/K013041/1)
- National Institute on Aging (P30AG008051, P50AG008702, P50AG005136, P50AG005134, P30AG062421)
- National Institute of Neurological Disorders and Stroke (R01NS080820)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- bapineuzumab, Alzheimer's disease, anti-amyloid beta monoclonal antibody, APOE ε4 carriers, amyloid-related imaging abnormalities, amyloid PET, Pittsburgh compound B, phosphorylated tau, cognitive impairment, functional disability, treatment discontinuation, mild to moderate Alzheimer's disease
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Apolipoproteins E, Brain, Cognition, Double-Blind Method, Edema, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Phosphorylation, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Treatment Failure, Positron-Emission Tomography, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.